The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia

Eur Respir J. 2014 Jul;44(1):239-41. doi: 10.1183/09031936.00220413. Epub 2014 Mar 23.

¹ GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA hector.g.ortega@gsk.com.
² Dept of Pulmonary and Critical Care, Yale University Medical School, Winchester Chest Clinic, 20 York Street, New Haven, CT, USA.
³ Monash University and Medical Centre, Lung and Sleep, Melbourne, Australia.
⁴ Dept of Allergy, Hospital Arnaud de Villeneuve, Montpellier, France.
⁵ University Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France AP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
⁶ GlaxoSmithKline, Research and Development, Stockley Park, Middlesex, UK.
⁷ GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA.
⁸ University Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France AP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France Inserm U999, LabEx LERMIT, Le Plessis Robinson, France.

No abstract available

Publication types